泽璟制药(688266.SH)：注射用ZG005与含铂化疗联用获得药物临床试验批准通知书

Core Viewpoint - Zai Lab (688266.SH) has received approval from the National Medical Products Administration for clinical trials of ZG005, a novel dual-specific antibody targeting PD-1 and TIGIT, for use in advanced nasopharyngeal carcinoma and esophageal squamous cell carcinoma [1] Group 1: Product Information - ZG005 is a recombinant humanized anti-PD-1/TIGIT dual-specific antibody classified as a Class 1 innovative tumor immunotherapy biological product [1] - ZG005 is among the first in the world to enter clinical research for this target mechanism, with no similar mechanism drugs approved globally [1] Group 2: Mechanism of Action - ZG005 simultaneously blocks PD-1 and TIGIT pathways, enhancing T cell activation and proliferation by inhibiting PD-1 signaling through its ligand PD-L1 [1] - The drug also effectively blocks the TIGIT pathway, promoting co-stimulatory activation signals through PVR and CD226, leading to increased activation and proliferation of T cells and NK cells [1] - The dual-target blockade is expected to synergistically enhance the immune system's ability to kill tumor cells [1]